Marchiafava-Bignami disease

Marchiafava-Bignami disease (MBD) is a rare neurological disorder characterized by progressive demyelination and necrosis of the corpus callosum, the major white matter structure connecting the two hemispheres of the brain. Although historically associated with chronic alcoholism and nutritional deficiency, particularly in malnourished individuals who consume large quantities of red wine, the condition has also been reported in non-alcoholic patients with other causes of malnutrition or metabolic derangement. The disease primarily affects the central nervous system, with damage centered on the corpus callosum but sometimes extending to other white matter tracts. Clinical presentation varies widely and can be acute, subacute, or chronic. Acute forms may present with seizures, altered consciousness, stupor, or coma, and can be rapidly fatal. Subacute and chronic forms may manifest with cognitive decline, dementia, dysarthria (difficulty speaking), gait disturbances, muscle rigidity or spasticity, interhemispheric disconnection syndromes (where the two brain hemispheres fail to communicate properly), and psychiatric symptoms including apathy and depression. Diagnosis is primarily made through magnetic resonance imaging (MRI), which reveals characteristic lesions in the corpus callosum. There is no specific cure for Marchiafava-Bignami disease. Treatment is largely supportive and focuses on addressing the underlying cause, particularly alcohol cessation and nutritional rehabilitation. High-dose thiamine (vitamin B1) supplementation and correction of other nutritional deficiencies, including folate and vitamin B12, are standard components of management. Corticosteroids have been used in some acute cases with reported benefit, though evidence remains limited to case reports and small case series. Prognosis is variable; some patients recover partially or fully with prompt treatment, while others experience permanent neurological deficits or death, particularly in the acute fulminant form.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Marchiafava-Bignami disease